NYSE:MRK - Merck & Co. Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$58.45 -0.12 (-0.20 %)
(As of 05/23/2018 08:28 AM ET)
Previous Close$58.57
Today's Range$58.40 - $59.14
52-Week Range$52.83 - $66.41
Volume8.57 million shs
Average Volume10.25 million shs
Market Capitalization$157.92 billion
P/E Ratio14.69
Dividend Yield3.28%
Beta0.76

About Merck & Co. (NYSE:MRK)

Merck & Co. logoMerck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:MRK
CUSIP58933Y10
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.63
Current Ratio1.42
Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio14.69
Forward P/E Ratio13.82
P/E Growth2.23

Sales & Book Value

Annual Sales$40.12 billion
Price / Sales3.93
Cash Flow$5.7024 per share
Price / Cash10.25
Book Value$12.57 per share
Price / Book4.65

Profitability

EPS (Most Recent Fiscal Year)$3.98
Net Income$2.39 billion
Net Margins4.31%
Return on Equity30.93%
Return on Assets12.66%

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000

Merck & Co. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co.'s stock symbol?

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co. pay dividends? What is the dividend yield for Merck & Co.?

Merck & Co. declared a quarterly dividend on Tuesday, May 22nd. Investors of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a yield of 3.28%. View Merck & Co.'s Dividend History.

How will Merck & Co.'s stock buyback program work?

Merck & Co. declared that its board has initiated a stock repurchase plan on Saturday, December 2nd 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

How were Merck & Co.'s earnings last quarter?

Merck & Co. (NYSE:MRK) posted its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.05. The firm had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.09 billion. Merck & Co. had a net margin of 4.31% and a return on equity of 30.93%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 EPS. View Merck & Co.'s Earnings History.

When is Merck & Co.'s next earnings date?

Merck & Co. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co..

What guidance has Merck & Co. issued on next quarter's earnings?

Merck & Co. updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

What price target have analysts set for MRK?

18 brokerages have issued twelve-month price targets for Merck & Co.'s stock. Their predictions range from $56.00 to $72.00. On average, they anticipate Merck & Co.'s share price to reach $65.8644 in the next year. View Analyst Ratings for Merck & Co..

Are investors shorting Merck & Co.?

Merck & Co. saw a decrease in short interest during the month of April. As of April 30th, there was short interest totalling 20,402,734 shares, a decrease of 11.1% from the April 13th total of 22,946,449 shares. Based on an average trading volume of 13,648,624 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.8% of the company's stock are short sold.

Who are some of Merck & Co.'s key competitors?

Who are Merck & Co.'s key executives?

Merck & Co.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
  • Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)
  • Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54)

Has Merck & Co. been receiving favorable news coverage?

Headlines about MRK stock have trended positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merck & Co. earned a media sentiment score of 0.37 on Accern's scale. They also gave headlines about the company an impact score of 47.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Merck & Co.'s major shareholders?

Merck & Co.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.85%), Franklin Resources Inc. (1.82%), Northern Trust Corp (1.24%), Boston Partners (0.55%), Legal & General Group Plc (0.50%) and Barrow Hanley Mewhinney & Strauss LLC (0.47%). Company insiders that own Merck & Co. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co..

Which major investors are selling Merck & Co. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Federated Investors Inc. PA, Northern Trust Corp, Boston Partners, Barrow Hanley Mewhinney & Strauss LLC, Swiss National Bank, Independent Franchise Partners LLP and Legal & General Group Plc. Company insiders that have sold Merck & Co. company stock in the last year include Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co..

Which major investors are buying Merck & Co. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Pzena Investment Management LLC, Natixis, Manning & Napier Group LLC, Levin Capital Strategies L.P., American Century Companies Inc., Sound Shore Management Inc. CT and Summit Trail Advisors LLC. View Insider Buying and Selling for Merck & Co..

How do I buy shares of Merck & Co.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co.'s stock price today?

One share of MRK stock can currently be purchased for approximately $58.45.

How big of a company is Merck & Co.?

Merck & Co. has a market capitalization of $157.92 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co. employs 69,000 workers across the globe.

How can I contact Merck & Co.?

Merck & Co.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co. (MRK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  612 (Vote Outperform)
Underperform Votes:  637 (Vote Underperform)
Total Votes:  1,249
MarketBeat's community ratings are surveys of what our community members think about Merck & Co. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merck & Co. (NYSE:MRK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Merck & Co. in the last 12 months. Their average twelve-month price target is $65.8644, suggesting that the stock has a possible upside of 12.68%. The high price target for MRK is $72.00 and the low price target for MRK is $56.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.782.782.562.44
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.8644$65.5519$66.1250$66.20
Price Target Upside: 12.68% upside11.43% upside21.22% upside21.76% upside

Merck & Co. (NYSE:MRK) Consensus Price Target History

Price Target History for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00LowView Rating Details
4/25/2018Deutsche BankReiterated RatingHoldLowView Rating Details
4/23/2018Goldman SachsUpgradeNeutral ➝ Buy$60.15 ➝ $58.83LowView Rating Details
4/20/2018CowenReiterated RatingHold$67.00LowView Rating Details
4/17/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$68.00 ➝ $70.00LowView Rating Details
4/17/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$59.80 ➝ $63.00LowView Rating Details
4/13/2018Jefferies GroupSet Price TargetHold$56.00LowView Rating Details
4/5/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $64.00LowView Rating Details
3/12/2018Leerink SwannUpgradeMarket Perform ➝ OutperformLowView Rating Details
2/14/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$66.00 ➝ $65.00LowView Rating Details
2/13/2018DZ BankUpgradeHold ➝ BuyLowView Rating Details
1/16/2018SunTrust BanksUpgradeHold ➝ Buy$54.00 ➝ $72.00HighView Rating Details
11/15/2017Sanford C. BernsteinReiterated RatingBuy$64.00N/AView Rating Details
11/1/2017Berenberg BankReiterated RatingHoldN/AView Rating Details
10/30/2017CitigroupUpgradeBuyN/AView Rating Details
10/30/2017UBSLower Price TargetBuy$72.00 ➝ $67.00N/AView Rating Details
10/29/2017JPMorgan ChaseSet Price TargetBuy$70.00N/AView Rating Details
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00LowView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral ➝ Buy$61.63 ➝ $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 ➝ $80.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Merck & Co. (NYSE:MRK) Earnings History and Estimates Chart

Earnings by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Earnings Estimates

2018 EPS Consensus Estimate: $4.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.96$1.01$0.99
Q2 20182$1.06$1.11$1.09
Q3 20182$1.09$1.13$1.11
Q4 20182$0.97$1.05$1.01

Merck & Co. (NYSE MRK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2018N/AView Earnings Details
5/1/2018Q1 2018$0.9980$1.05$10.0884 billion$10.0370 billionViewN/AView Earnings Details
2/2/2018Q4 2017$0.94$0.98$10.4850 billion$10.4330 billionViewListenView Earnings Details
10/27/2017Q3 2017$1.03$1.11$10.5450 billion$10.3250 billionViewN/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.7463 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.2539 billion$9.4340 billionViewListenView Earnings Details
2/2/2017Q416$0.8890$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
10/29/2010Q3 2010$0.83$0.85ViewN/AView Earnings Details
7/30/2010Q2 2010$0.82$0.86ViewN/AView Earnings Details
5/4/2010Q1 2010$0.75$0.84ViewN/AView Earnings Details
2/16/2010Q4 2009$0.78$0.80ViewN/AView Earnings Details
10/22/2009Q3 2009$0.82$0.90ViewN/AView Earnings Details
7/21/2009Q2 2009$0.78$0.83ViewN/AView Earnings Details
4/21/2009Q1 2009$0.77$0.74ViewN/AView Earnings Details
2/3/2009Q4 2008$0.74$0.87ViewN/AView Earnings Details
10/22/2008Q3 2008$0.79$0.80ViewN/AView Earnings Details
7/21/2008Q2 2008$0.83$0.86ViewN/AView Earnings Details
4/21/2008Q1 2008$0.85$0.89ViewN/AView Earnings Details
1/30/2008Q4 2007$0.73$0.80ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Merck & Co. (NYSE:MRK) Dividend Information

Merck & Co. pays an annual dividend of $1.92 per share, with a dividend yield of 3.28%. MRK's next quarterly dividend payment will be made on Monday, July 9. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 2.20% each year. Merck & Co. pays out 48.24% of its earnings out as a dividend.
Next Dividend:7/9/2018
Annual Dividend:$1.92
Dividend Yield:3.28%
Dividend Growth:2.20% (3 Year Average)
Payout Ratio(s):48.24% (Trailing 12 Months of Earnings)
45.39% (Based on This Year's Estimates)
42.67% (Based on Next Year's Estimates)
33.67% (Based on Cash Flow)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2018quarterly$0.483.28%6/15/20187/9/2018
1/23/2018quarterly$0.483.52%3/14/20183/15/20184/6/2018
11/28/2017quarterly$0.4812/14/201712/15/20171/8/2018
7/25/2017quarterly$0.479/14/20179/15/201710/6/2017
5/23/2017quarterly$0.472.9%6/13/20176/15/20177/10/2017
2/28/2017quarterly$0.473/13/20173/15/20174/7/2017
11/22/2016quarterly$0.473.05%12/13/201612/15/20161/9/2017
7/26/2016quarterly$0.463.14%9/13/20169/15/201610/7/2016
5/24/2016quarterly$0.463.25%6/13/20166/15/20167/8/2016
2/23/2016quarterly$0.463.64%3/11/20163/15/20164/7/2016
11/24/2015quarterly$0.463.43%12/11/201512/15/20151/8/2016
7/22/2015quarterly$0.453.1%9/11/20159/15/201510/7/2015
5/26/2015quarterly$0.453.03%6/11/20156/15/20157/8/2015
2/24/2015quarterly$0.453.05%3/12/20153/16/20154/8/2015
11/25/2014quarterly$0.453.01%12/11/201412/15/20141/8/2015
7/23/2014quarterly$0.443.02%9/11/20149/15/201410/7/2014
5/27/2014quarterly$0.443.12%6/12/20146/16/20147/8/2014
2/25/2014quarterly$0.443.13%3/13/20143/17/20144/7/2014
11/26/2013quarterly$0.443.53%12/12/201312/16/20131/8/2014
7/24/2013quarterly$0.433.57%9/12/20139/16/201310/7/2013
5/28/2013quarterly$0.433.67%6/13/20136/17/20137/8/2013
2/26/2013quarterly$0.434%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Merck & Co. (NYSE MRK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 73.14%
Insider Trading History for Merck & Co. (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE MRK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Julie L. GerberdingEVPSell9,972$59.66$594,929.52View SEC Filing  
4/16/2018Weir Mirian M. GraddickInsiderSell24,000$58.00$1,392,000.00View SEC Filing  
2/9/2018Wendell P WeeksDirectorSell5,000$53.57$267,850.005,100View SEC Filing  
1/16/2018Michael J. HolstonEVPSell12,500$61.63$770,375.00View SEC Filing  
1/16/2018Weir Mirian M GraddickInsiderSell60,000$61.63$3,697,800.00101,484View SEC Filing  
1/12/2018Weir Mirian M GraddickInsiderSell5,000$58.00$290,000.00101,484View SEC Filing  
11/8/2017Thomas H GlocerDirectorSell5,000$56.20$281,000.00View SEC Filing  
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.0014,317View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.0018,148View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.005,100View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64105,559View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.005,100View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00514,957View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.4677,762View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.009,594View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00128,973View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.0039,200View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00760,877View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00554,856View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00123,151View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.0050,000View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00162,151View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.8317,083View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40653,517View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00100View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.0419,695View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54438,236View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.001,000View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28310,494View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75121,845View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.306,046View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.8027,587View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.0010,697View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40262,829View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.001,000View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00106,049View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90106,040View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Merck & Co. (NYSE MRK) News Headlines

Source:
DateHeadline
Competitive Pressure And Lower Demand Will Likely Weigh On Mercks Anti-Infective Drug PortfolioCompetitive Pressure And Lower Demand Will Likely Weigh On Merck's Anti-Infective Drug Portfolio
www.forbes.com - May 22 at 4:24 PM
Merck Announces Third-Quarter 2018 DividendMerck Announces Third-Quarter 2018 Dividend
finance.yahoo.com - May 22 at 4:24 PM
Merck & Co. (MRK) Declares $0.48 Quarterly DividendMerck & Co. (MRK) Declares $0.48 Quarterly Dividend
www.americanbankingnews.com - May 22 at 4:00 PM
7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All
finance.yahoo.com - May 21 at 4:25 PM
[$$] Ebola Vaccination Begins in Democratic Republic of Congo[$$] Ebola Vaccination Begins in Democratic Republic of Congo
finance.yahoo.com - May 21 at 4:25 PM
Factbox - From sterling crises to Brexit, the tests of Bank of England bossesFactbox - From sterling crises to Brexit, the tests of Bank of England bosses
finance.yahoo.com - May 21 at 4:25 PM
Congo begins giving experimental Ebola vaccine to medicsCongo begins giving experimental Ebola vaccine to medics
finance.yahoo.com - May 21 at 4:25 PM
Dispute on eye drop size fails to catch Supreme Courts eyeDispute on eye drop size fails to catch Supreme Court's eye
marketbeat.com - May 21 at 9:55 AM
Congo to begin Ebola vaccinations on Monday - health ministryCongo to begin Ebola vaccinations on Monday - health ministry
finance.yahoo.com - May 20 at 9:52 AM
Gilead Sciences’ Cash Flows, Valuations, and Price PerformanceGilead Sciences’ Cash Flows, Valuations, and Price Performance
finance.yahoo.com - May 17 at 9:46 AM
Merck & Co. (MRK) EVP Sells $594,929.52 in StockMerck & Co. (MRK) EVP Sells $594,929.52 in Stock
www.americanbankingnews.com - May 16 at 1:19 PM
Zacks Investment Research Downgrades Merck & Co. (MRK) to HoldZacks Investment Research Downgrades Merck & Co. (MRK) to Hold
www.americanbankingnews.com - May 16 at 11:04 AM
Merck & Co. (MRK) Sees Large Decline in Short InterestMerck & Co. (MRK) Sees Large Decline in Short Interest
www.americanbankingnews.com - May 16 at 1:08 AM
Ebola Vaccine Headed to Congo to Help Contain OutbreakEbola Vaccine Headed to Congo to Help Contain Outbreak
finance.yahoo.com - May 15 at 4:23 PM
Merck KGaAs sales hit by currency headwindsMerck KGaA's sales hit by currency headwinds
www.marketwatch.com - May 15 at 10:06 AM
Merck KGaA sales hurt by currency, China headwindsMerck KGaA sales hurt by currency, China headwinds
www.marketwatch.com - May 15 at 10:06 AM
Merck & Co Inc. (NYSE:MRK) Is Trading At A 31% DiscountMerck & Co Inc. (NYSE:MRK) Is Trading At A 31% Discount
finance.yahoo.com - May 15 at 10:06 AM
Bristol-Myers Squibb’s Cash Flows and Valuation MetricsBristol-Myers Squibb’s Cash Flows and Valuation Metrics
finance.yahoo.com - May 15 at 10:06 AM
Keytruda Continues To Be The Game Changer For Merck In 2018Keytruda Continues To Be The Game Changer For Merck In 2018
seekingalpha.com - May 14 at 10:56 AM
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
finance.yahoo.com - May 14 at 10:56 AM
Is Agenus Inc. (AGEN) a Buy?Is Agenus Inc. (AGEN) a Buy?
finance.yahoo.com - May 12 at 10:05 AM
Merck & Co. (MRK) Expected to Post Quarterly Sales of $10.40 BillionMerck & Co. (MRK) Expected to Post Quarterly Sales of $10.40 Billion
www.americanbankingnews.com - May 12 at 2:58 AM
Merck, Verizon Pace the Dow FridayMerck, Verizon Pace the Dow Friday
247wallst.com - May 11 at 4:33 PM
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
finance.yahoo.com - May 11 at 10:41 AM
US stock indexes edge higher in early trading; oil downUS stock indexes edge higher in early trading; oil down
finance.yahoo.com - May 11 at 10:41 AM
WHO hopes to use Ebola vaccine to stem outbreak in remote area of CongoWHO hopes to use Ebola vaccine to stem outbreak in remote area of Congo
finance.yahoo.com - May 11 at 10:41 AM
How Much Upside Potential Does Celgene Offer?How Much Upside Potential Does Celgene Offer?
finance.yahoo.com - May 10 at 4:25 PM
$1.04 Earnings Per Share Expected for Merck & Co. (MRK) This Quarter$1.04 Earnings Per Share Expected for Merck & Co. (MRK) This Quarter
www.americanbankingnews.com - May 10 at 11:20 AM
How Valeant Pharmaceuticals Performed in 1Q18How Valeant Pharmaceuticals Performed in 1Q18
finance.yahoo.com - May 9 at 9:35 AM
A Overview of Merck’s Diabetes Products in 1Q18A Overview of Merck’s Diabetes Products in 1Q18
finance.yahoo.com - May 9 at 9:35 AM
Merck and AstraZeneca Announced EMA Approval for LynparzaMerck and AstraZeneca Announced EMA Approval for Lynparza
finance.yahoo.com - May 8 at 4:24 PM
Merck Wastes No Time Waiting For End Results, Files For Approval ImmediatelyMerck Wastes No Time Waiting For End Results, Files For Approval Immediately
seekingalpha.com - May 8 at 9:33 AM
MRK :EU Oks LYNPARZA Tablets To Treat Platinum-Sensitive Relapsed Ovarian CancerMRK :EU Oks LYNPARZA Tablets To Treat Platinum-Sensitive Relapsed Ovarian Cancer
www.nasdaq.com - May 8 at 9:33 AM
Will Elanco’s Top-Line Growth Return in 2018?Will Elanco’s Top-Line Growth Return in 2018?
finance.yahoo.com - May 8 at 9:33 AM
Alimta: An Emerging Drug to Treat Lung CancerAlimta: An Emerging Drug to Treat Lung Cancer
finance.yahoo.com - May 7 at 4:27 PM
Provectus Biopharma (PVCT) Reports Complete Enrollment of Phase 1B Trial of PV-10 in Combination with Mercks (MRK) KeytrudaProvectus Biopharma (PVCT) Reports Complete Enrollment of Phase 1B Trial of PV-10 in Combination with Merck's (MRK) Keytruda
www.streetinsider.com - May 7 at 10:06 AM
Merck & Co. (MRK) Receives Average Recommendation of "Buy" from BrokeragesMerck & Co. (MRK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 6 at 8:00 PM
Merck & Co Inc. (NYSE:MRK): Time For A Financial Health CheckMerck & Co Inc. (NYSE:MRK): Time For A Financial Health Check
finance.yahoo.com - May 6 at 9:41 AM
BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines CollaborationBRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration
www.reuters.com - May 5 at 4:26 PM
Merck: Getting StrongerMerck: Getting Stronger
seekingalpha.com - May 4 at 4:27 PM
Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on EarningsDow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings
www.nasdaq.com - May 4 at 9:27 AM
How Analysts View AmgenHow Analysts View Amgen
finance.yahoo.com - May 4 at 9:27 AM
Eli Lilly Shares Seen Rising 18% as Profits SurgeEli Lilly Shares Seen Rising 18% as Profits Surge
finance.yahoo.com - May 4 at 9:27 AM
Biotech unicorn Moderna raises another $125M from partner MerckBiotech unicorn Moderna raises another $125M from partner Merck
finance.yahoo.com - May 4 at 9:27 AM
SunTrust Banks Comments on Merck & Co.s Q2 2018 Earnings (MRK)SunTrust Banks Comments on Merck & Co.'s Q2 2018 Earnings (MRK)
www.americanbankingnews.com - May 4 at 7:36 AM
Moderna and Merck Expand mRNA Cancer Vaccines CollaborationModerna and Merck Expand mRNA Cancer Vaccines Collaboration
finance.yahoo.com - May 3 at 4:21 PM
Merck Updates On KEYNOTE-407 TrialMerck Updates On KEYNOTE-407 Trial
www.nasdaq.com - May 3 at 9:28 AM
Merck Provides Update on KEYNOTE-407 TrialMerck Provides Update on KEYNOTE-407 Trial
finance.yahoo.com - May 3 at 9:28 AM
Eli Lilly Could Report Robust Rise in Net Profit Margins in 2018Eli Lilly Could Report Robust Rise in Net Profit Margins in 2018
finance.yahoo.com - May 2 at 9:29 AM
Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises OutlookMerck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook
finance.yahoo.com - May 1 at 4:21 PM

SEC Filings

Merck & Co. (NYSE:MRK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merck & Co. (NYSE:MRK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merck & Co. (NYSE MRK) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.